We have observed
16 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after July 14, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
METHOD FOR POLYCLONAL STIMULATION OF T CELLS BY MOBILE NANOMATRICES
SSEA4 and ST3GAL2 as chemotherapeutic drug response biomarkers
Method for generation of a cell composition of mesencephalic dopaminergic progenitor cells
HUMANIZED ANTIBODY OR FRAGMENT THEREOF SPECIFIC FOR CD3
A METHOD FOR ANALYSING MARKERS ON THE SURFACE OF VESICLES
METHOD FOR AUTOMATED GENERATION OF GENETICALLY MODIFIED T CELLS
METHOD FOR NATURAL KILLER CELL EXPANSION
CHIMERIC ANTIGEN RECEPTOR WITH CYTOKINE RECEPTOR ACTIVATING OR BLOCKING DOMAIN
CHIMERIC ANTIGEN RECEPTOR SPECIFIC FOR SSEA4 ANTIGEN
METHOD FOR INTRODUCING NUCLEIC ACIDS INTO A CELL
COMPOSITION AND METHOD FOR AFFECTING THE BINDING OF ANTIGEN-BINDING POLYPEPTIDES TO ANTIGENS
ADAPTER CHIMERIC ANTIGEN RECEPTOR EXPRESSING CELLS FOR TARGETING OF MULTIPLE ANTIGENS
REVERSIBLE LABELING OF ANTIGENS IN BIOLOGICAL SPECIMENS
IMMUNE CELLS EXPRESSING AN ANTIGEN BINDING RECEPTOR AND A CHIMERIC COSTIMULATORY RECEPTOR